Advanced ovarian cancers are a leading cause of cancer-related death in women. Such cancers are currently treated with surgery and chemotherapy which is often temporarily successful but exhibits a high rate of relapse after which treatment options are few. Here we assess the responses of a panel of patient-derived ovarian cancer xenografts (PDXs) to 19 mono and combination therapies, including small molecules and antibody-drug conjugates. The PDX panel aimed to mimic the heterogeneity of disease observed in patients, and exhibited a distribution of responsiveness to standard of care chemotherapy similar to human clinical data. Three monotherapies and one drug combination were found to be active in different subsets of PDXs. By analyzing gene expression data we identified gene expression biomarkers predictive of responsiveness to each of three novel targeted therapy regimens.
INTRODUCTION
Epithelial ovarian cancer is among the leading causes of cancer-related death in women. The high mortality of this cancer reflects the fact that it is often at an advanced stage when diagnosed, and relatively few effective therapies are available for recurrent disease 1 . The most common treatment for advanced-stage epithelial ovarian cancer is surgical resection (if possible) followed by taxane/platinumbased chemotherapy. A high percentage of patients respond initially but the disease usually relapses and 5-year survival is around 30% 2, 3 . Angiogenesis inhibitors and PARP inhibitors have improved survival 4 though not cure rates, and overall the past decade has seen few new therapeutic strategies, emphasizing a pressing unmet medical need.
The difficulty in developing targeted therapies for epithelial ovarian cancers arises in part because the mutational spectrum of the disease does not exhibit many recurrent mutations in genes that might make attractive therapeutic targets; this is in contrast to other types of cancer for which therapies have been developed for specific, biomarker defined subtypes (e.g. lung adenocarcinoma, chronic and acute myeloid leukemia, melanoma, HER2 + breast cancer). In ovarian cancers, mutations in the P53 and homologous recombination repair pathways are common (96% and 22% of tumors respectively), but few patients have additional mutations that that can currently be used to guide therapy (reviewed in Coward et al, 2015 4 ). Ovarian cancers nonetheless display substantial inter-patient heterogeneity in therapeutic response, suggesting the existence of as-yet unrecognized determinants of drug sensitivity and resistance and the potential for personalized treatment regimens. Preclinical models that reflect the heterogeneous biology of this ovarian cancer have the potential to change this situation by providing data on therapeutic vulnerabilities that can be associated with specific biomarkers.
In contrast to cell lines and conventional xenografts, patient-derived xenografts (PDXs) often preserve Page 5 histopathologic and genetic features of human tumors at the time of their resection. PDX models are not an ideal mimic of human disease, in part because xenografting human tumors requires the use of mice that lack functional adaptive immune systems, but measures of drug efficacy in PDXs such as changes in tumor volume and duration of progression-free survival (PFS)) more closely resemble clinical responses than conventional xenografts or studies with cell lines. In particular, as data in this study will show, ovarian tumor PDXs recapitulate the clinically known association between BRCA loss-offunction mutations and sensitivity to the PARP inhibitor Olaparib, which has not been reproduced in panels of ovarian cancer cell lines ( Supplementary Fig. S1 5-7 ). PDX-based preclinical studies of patient to-patient variability in drug response have been reported for lung, breast, colon, melanoma and pancreatic cancers, including a previously described encyclopedia of >1000 PDXs [8] [9] [10] . Here we report for the first time the in vivo therapeutic effects of 19 different treatments, including single agents and combinations, using a panel of well-characterized ovarian PDXs from this encyclopedia. We then associated differences in response with differences in tumor gene expression, making it possible to nominate potential biomarkers for ovarian cancers. We found that a majority of ovarian PDX tumors have transcriptional or genomic biomarkers that can be used to guide the selection of treatment that elicits tumor regression as great as that associated with responses to standard of care combination chemotherapy. Whether these biomarkers will translate into humans remains unknown, but our data strongly suggest the existence of new opportunities for biomarker-guided treatment of ovarian cancer.
The approach is analogous to genome-informed inhibition of oncogenes in non-small cell lung cancer 11 , but applicable to ovarian cancers and other possibly other cancers with few 'druggable' oncogenes by encompassing biomarkers of drug sensitivity that do not correspond to oncogenic drivers.
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METHODS
Generation of ovarian patient-derived xenografts
Mice were maintained and handled in accordance with the Novartis Institutes for BioMedical Research (NIBR) Animal Care and Use Committee protocols and regulations. Patient tumor specimens were obtained from: the National Disease Research Interchange, Philadelphia, PA, USA; the Cooperative Human Tissue Network funded by National Cancer Institute, Rockville, MD, USA; Maine Medical Center, Portland, ME, USA. All patients were provided informed consents, samples were procured and the study was conducted under the approval of the review boards of each institution. Clinical and pathologic data were entered and maintained in appropriate databases. Generation of the PDX encyclopedia has been reported previously 9 . Briefly, tumor samples resected from ovarian cancer patients were preserved in RPMI medium and implanted in mice within 24 hours post-surgery. About 30-50mg tumor fragments were subcutaneously implanted into the flank region of athymic nude mice (Crl: Nu(NCr)-Foxn1 nu ; Charles River Laboratories). Tumor growth was monitored twice per week and successfully engrafted tumors then propagated and banked after a serial passage (p3 or p4). Flash frozen and FFPE tumor fragments were collected and used for DNA/RNA extraction and histopathological evaluation, respectively. The identity of established PDXs (defined as models propagated at least three times in mice) was confirmed by SNP48 analysis before and after PDX Clinical Trial (PCT) studies, as reported previously 9 .
Histopathological characterization of established ovarian PDXs
Established PDXs and corresponding patient tumor samples were subjected to histopathologic examination. Freshly collected xenograft tumor samples and patient tumor samples preserved in RPMI were fixed in 10% neutral-buffered formalin for 6-24 h, processed, and paraffin embedded. FFPE sections were cut at 3.5 microns, mounted on slides, baked at 60 o C for at least 30 minutes, Page 7 deparaffinized and stained with hematoxylin and eosin. Images were captured using an Aperio Scanscope (Aperio Technologies).
Genomic profiling of ovarian PDXs
RNA and DNA from ~30 mg flash frozen tumor fragments was purified using the QIAcube (Qiagen cat# 9001292) automated sample preparation platform using the Qiagen ALLPrep DNA/RNA Mini Kit (cat# 80204). The RNA concentration and integrity was evaluated with an Agilent 2100 Bioanalyzer (cat #G2940CA) utilizing the Agilent RNA 6000 Nano Kit (cat# 5067-1511) and protocol. DNA quantification was assessed with the NanoDrop 8000.
Copy number analysis was derived from profiling of total DNA on the Affymetrix genome-wide human SNP Array 6.0 chip using instrumentation and protocols from Affymetrix. The raw CEL files were returned and the QC steps were performed using Affymetrix Genotyping Console. The CEL files from chips passing QC were used for copy number analysis. Both a copy number segmentation file and a gene-level copy number value was generated using Partek Genomic Suite 6. The FASTQ files were then processed as in Korpal et al. 12 , modified to align simultaneously to mm10 and GRCh37 genomes and transcriptomes to allow for both human (tumor) and mouse (stroma) alignment. Mutations were called only on GRCh37. For calculating mutation rates, non-COSMIC mutations that appeared in >50 samples across a larger collection of cell line and PDX models or in dbSNP v138 were removed as likely germline variants / false positives / alignment artifacts.
For TCGA, we downloaded somatic SNVs identified from whole exome sequencing and copy number alterations identified by Affymetrix SNP6.0 from the cBio portal.
PDX Clinical Trial (PCT) and drug treatment
Treatment of established ovarian PDXs in the PCT format was described previously 9 . Briefly, ovarian PDXs between passages 4-8 were used for the PCT study, and tumors (~200 mm 3 ) were enrolled on a rolling basis and treated till they reached the study end points. Maximum tolerated dose (MTD) was used for the agents that have not entered the clinics yet, while clinically relevant dose (CRD) was used for agents that are currently used or have been evaluated in the clinic. The CRD was converted from human dose by matching blood exposure (Supplementary Table 5 ). The standard treatment schedule was 21 days. Fast growing tumors were dosed till the tumors reached ~1500 mm 3 . For slow growing tumors, treatment was maintained until tumor volume doubled at least twice. Tumor size was evaluated twice weekly by caliper measurements and the approximate volume of the mass was calculated using the formula (L´W´W) ´ (π/6), where L is the major tumor axis and W is the minor tumor axis. The duration of 'Progression Free Survival' (PFS) was defined as the time on therapy until tumor volume doubled.
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In the absence of progression or an adverse event, treatment was continued for at least 150 days. The response was determined based on the defined criteria described previously 9 : mCR, BestResponse < −95% and BestAvgResponse < −40%; mPR, BestResponse < −50% and BestAvgResponse < −20%; mSD, BestResponse < 35% and BestAvgResponse < 30%; mPD, not otherwise categorized. Mice that were sacrificed because of an adverse event before they had completed 14d on trial were removed from the data set. Objective response rate (ORR) was calculated as the percent of PDXs with partial and complete responses (mPR + mCR) to each therapy.
To correct for variability in background growth rate between PDX models, we normalized the time scale of each model to the model-specific doubling time-that is, the day at which the unabated tumor is expected to double in volume. We approximated the model doubling time as the lowest 25 th percentile of the doubling times among successfully engrafted tumors of that model (defined as doubling in volume and maintaining a relative tumor volume greater than -20%). We used the approximated model doubling time as a scaling factor for all measured growth curve time points within each model. Each sampled time point in the normalized growth curve for a given model was calculated as follows:
Where , is the ith time point of normalized sample n, , is the ith time point of un-normalized sample u, and is the approximate doubling time of the model. Each normalized time point is multiplied by a factor of 10 to rescale the growth curves to approximate the original median doubling time from un-normalized growth curves. We additionally set a lower and upper limit for to 5 and 20, respectively.
Identifying drug combinations with stronger than independent action
Both PFS and tumor volume measurements were analyzed to determine if any drug combinations achieved a response better than their best constituent single-agent response, which is a standard that few combination therapies surpass in vivo 13 and is evidence of additive or synergistic effect. This analysis was performed for the 9 combinations which also had response data for their constituent monotherapies.
For the PFS analysis, a survival distribution was generated for the two PDX monotherapy responses that constituted a combination. To simulate the combination response expected by independent action 13 To determine statistical significance, we examined differences in responses to two PI3K inhibitors (BKM120 and CLR457) to estimate the magnitude of experimental error. A null distribution of differences in drug response was constructed by comparing tumor volume changes from BKM120 and CLR457 in 29 PDX models. For each combination therapy, volume changes expected by independent action were calculated by picking the best of the two constituent monotherapy volume changes for each PDX model. This resulting distribution of observed volume changes minus the expected independent action volume changes was compared to the null distribution (differences expected from experimental error). A Mann-Whitney test assessed whether the difference between the two volume difference distributions was significant and therefore whether the combination was significantly superior to independent action.
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Discovery of drug-response biomarkers
Identification of genes whose expression levels are predictive of drug sensitivity was performed separately for BKM120 plus binimetinib, LSU691, HKT288, and olaparib. Genes were selected that had highly variable in expression across the population of PDX tumors; specifically, those with variance in log2(transcript abundance in TPM) > 2. For each such high-variance gene, two metrics were calculated:
(1) the significance of association (-log10 P ) between transcript abundance and volume change (BestAvgResponse) by Spearman's rank correlation, and (2) the significance (-log10 P ) of the Hazard Ratio for disease progression between PDXs with less than median expression, and PDXs with greater or equal to median expression, by the Cox Proportional Hazards model. We elected not to explore different expression thresholds to avoid the risk of 'p-hacking'. On a scatterplot of -log10 P (association with tumor volume change) versus -log10 P (association with hazard ratio for PFS), the 20 genes at the Pareto frontier were selected, that is, those most strongly associated with both volume change and PFS.
For these genes, literature was searched for research articles describing the gene and the drug, or the gene and the drug's target. Genes were only considered candidate biomarkers if literature described a mechanistically plausible interaction that might determine drug response (for example, an efflux pump with known activity against the drug). Finally, the procedure was repeated with scrambled drug response labels 100 times per drug, and the fraction of cases was counted in which any gene exhibited equal or better significance of association with tumor volume change and PFS. A gene only remained a candidate biomarker if this procedure indicated a False Discovery Rate ≤ 25% for the statistical association with drug response. Given that few candidate genes found literature support for interacting with a drug, the False Discovery Rate for both statistical association and literature support is estimated to be <5%.
RESULTS
Ovarian PDXs recapitulate the histopathology and genomics of human epithelial ovarian cancers
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We established 49 ovarian PDXs representing a variety of histological subtypes ( Table 1) from treatment-naïve patient tumors. H&E staining of representative samples of each subtype showed that the PDXs closely recapitulated the histopathologic characteristics of the original patient tumors (Fig. 1a) except that human stroma were replaced by mouse stroma after two passages in mice, as previously reported for other ovarian PDX studies [14] [15] [16] .
To determine if tumors in the mouse PDX cohort were representative of the diversity of human disease, we generated transcript profiles by RNA-seq and copy number profiles for 27 of the high-grade serous
PDXs and compared them to data from 255 patients with high-grade serous tumors found in The Cancer
Genome Atlas (TCGA) 17 (Fig. 1b) . Transcripts were mapped simultaneously to either human (tumor) or mouse (stroma). The frequency of genetic alterations across the two datasets was similar. For instance, and relatively low mutation rates (Fig. 1b) . Genetic comparisons across all ovarian subtypes in PDXs (n = 38), cell lines (CCLE), and patient tumors (TCGA) is available in Supplementary Fig. S2 and Supplementary Table 1 . We conclude that our patient-derived tumor xenograft population is a representative sample of the genetic variability of human ovarian tumors.
Testing new therapies for ovarian cancer in PDX libraries
To identify new therapeutic strategies for advanced-stage epithelial ovarian cancer, 21 therapeutic approaches involving 10 single agents and 11 drug combinations (Supplementary Tables 2, 3 PR, and SD) was 81% in PDXs vs. 90% in humans. We found that all drugs and drug combinations tested were well-tolerated, with no significant drug-induced weight loss.
Page 14
The drug sensitivity landscape was heterogeneous: no single therapy had a better response rate than carboplatin/paclitaxel (62%), but 90% of tumors exhibited an objective response to at least one treatment ( Fig. 2, Supplementary Tables 1, 2, 3) . Change in tumor size was strongly correlated with duration of PFS (Spearman correlation -0.77, P = 10 -109 ). A number of novel combination therapies showed promising activity; in nine cases it was possible to compare the activity of a combination with its constituent drugs administered individually to determine whether its activity surpassed independent action (in which bet hedging allows populations to benefit from the best of multiple monotherapy activities 13 ). Activity surpassing independence is evidence of drug synergy or additivity. When each individual tumor's response to a combination therapy was compared to the best of its responses to the single drugs in that combination, changes in tumor volume and PFS were no better than monotherapy responses for eight of nine combinations, except for a combination of the PI3K inhibitor BKM120 and MEK inhibitor binimetinib ( Supplementary Table 4 ). Notably, three PI3K inhibitors (BKM120, BYL719, and CLR457) when used as monotherapies resulted in modest and short-lived responses (by tumor volume and PFS respectively), as previously observed in human ovarian cancer 18 . In contrast, BKM120 plus binimetinib (Fig. 3a) was superior to either drug alone and to a model of independent action with respect to both changes in tumor volume ( Fig. 3c) and duration of progression-free survival (Fig. 3b) . The BKM120 plus binimetinib combination achieved 48% ORR as compared to 21% for BKM120 and 4% for binimetinib, and a median PFS >100 days as compared to 43 or 14 days. For the combination vs. BKM120 alone, the hazard ratio (HR) was 0.24 (P=0.01 log-rank test) and for the combination vs. binimetinib alone, the Hazard Ratio (HR)=0.09 (P=10 -5 ); relative to an independent action model, the combination achieved an HR=0.27 (P=0.01) demonstrating highly superior activity ( Supplementary Table 3 ). Synergy between PI3K and MEK inhibitors in PDX tumors is consistent with extensive evidence that the MAPK and PI3K pathways interact and that MAPK activation can mediate resistance to PI3K inhibitors 18 .
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Three drugs elicited objective responses in 25% or more of ovarian PDXs as single agents: (i) HKT288, an antibody-drug conjugate directed against Cadherin 6 (CDH6) (whose development we recently described 19 ), (ii) LSU691, a small molecule inhibitor of Nicotinamide Phosphoribosyltransferase (NAMPT), and (iii) Olaparib, a small molecule inhibitor of Poly-ADP-Ribose Polymerases (PARP). In PDX trials it is possible to compare directly the response of a single tumor to different drugs and this showed that HKT288, LSU691, and BKM120 plus binimetinib induced responses in different sets of tumors, including those that were resistant to chemotherapy (Fig. 2) . As a result, 88% of tumors responded to either HKT288, LSU691, olaparib, or BKM120/binimetinib in contrast to a 62% response rate for carboplatin/paclitaxel chemotherapy. While our data suggest these targeted therapies may collectively be active against a larger proportion of tumors than standard chemotherapy, for this observation to be clinically useful a means to guide drug choice is required.
Identifying biomarkers for targeted therapies using PDX libraries
To identify predictors of drug response we compared treatment data for PDX models with RNAseq profiles. We limited the search to ~5000 protein-coding genes having a high variance in transcript abundance between PDX models. For each gene we calculated the significance of the correlation between transcript expression and treatment-induced changes in tumor volume change, and the significance of response duration (as assessed by hazard ratio) between tumors with higher or lower than median expression (Methods). We considered a gene a candidate response biomarker if it satisfied three criteria: (1) the gene was at the 'Pareto front' of significance -that is, among the 20 most significant in correlating with volume change and response duration; (2) the statistical association had a false discovery rate below 25%, based on simulations in which drug responses were scrambled among This procedure revealed candidate biomarkers for all four targeted therapies. Resistance to BKM120 plus binimetinib was predicted by high expression of the multi-drug efflux pump ABCG2 (Fig. 4a) .
Binimetinib and similar MEK inhibitors are known to be substrates of ABCG2 20 and we found that the association with resistance was independently supported by binimetinib responsiveness in a panel of breast cancer PDXs 21 (correlation of ABCG2 expression with volume change ρ=0.33, P=0.046, n=37;
proportional hazard of low vs high ABCG2 groups HR=0.50, P=0.08) (Fig. 4b) . Sensitivity to the NAMPT inhibitor LSU691 was predicted by high expression of HCLS1, an anti-apoptotic protein that is activated by the NAMPT/NAD + /SIRT1 pathway. This interaction has previously been proposed as a therapeutic target in leukemia 22 and our data suggests that it also affects responses to NAMPT inhibition in ovarian tumors. Sensitivity to the CDH6-targeting antibody HKT288 is predicted by high expression of CDH6 itself, as was previously reported based on CDH6 immunohistochemistry 19 . Finally, the best predictor of olaparib response is loss of BRCA1 and/or BRCA2 function (defined here as mutation of BRCA1 or BRCA2, or silencing of the BRCA1 transcript 23 ) ( Fig. 4) . BRCA1/2 loss is a clinically validated biomarker of olaparib response 24 and reproducing this association serves as a validation of our PDX-based approach. In contrast, our analysis of cancer cell line studies finds they contain no such association (Supplementary Fig. S1 ). Our search for predictive transcripts identified USP51 expression as being similarly predictive as BRCA loss-of-function; USP51 is recruited to double-strand breaks and regulates responses to DNA damage, including the assembly and disassembly of BRCA1 foci 25 . These data suggest that a simple test involving measuring the levels of four transcripts might be sufficient to identify tumors with a higher than average rates of response to four targeted therapies. Moreover, when PDX tumors were divided into 'treatment-eligible' or 'treatment ineligible' groups based on these Page 17 biomarkers (BRCA loss-of-function was used for olaparib), response rates were high in eligible PDX tumors (ORR 58% to 77%) and low in ineligible tumors (ORR 0% to 11%) (Fig. 4b) .
We then used TCGA primary tumor transcriptional and survival data to test whether these four biomarkers are associated with the rate of disease progression. When we compared the proportion of disease-free patients in the biomarker positive and negative groups for ABCG2, HCLS1, CDH6, and BRCA1/2, no biomarker was predictive of disease-free duration (Supplementary Fig. S3) . Thus, the biomarkers appear to be predictive of drug responses, not the rapidity of disease progression.
Most ovarian PDXs are candidates for biomarker-guided treatments
A large majority of PDX tumors (89%) were biomarker-positive candidates for one or more of four therapies: BKM120 plus binimetinib, LSU691, HKT288, or olaparib (Fig. 5a) . Analysis of the same biomarkers in human primary epithelial ovarian cancers (n= 232) in The Cancer Genome Atlas revealed that a similar fraction of human tumors (93%) are positive for one or more of the same biomarkers.
Furthermore, the proportion of biomarker positive tumors in TCGA did not significantly differ between rapidly progressing disease (less than 12 months disease-free) and better controlled disease (greater than 12 months disease-free), suggesting that biomarker-guided targeted therapies may be options in tumors responsive to chemotherapy as well as primary progressive disease (Fig. 5a) . Among PDX tumors, 19%
were ineligible or did not respond to a biomarker-indicated treatment, 33% experienced disease control from one indicated treatment, and 48% had disease control from two or more indicated treatments.
When each PDX tumor was assigned its one best biomarker-indicated treatment response (by tumor volume change), the resulting set of responses was comparable to the highly effective treatment of carboplatin/paclitaxel, both by volume change (Fig. 5b. 5c ; no significant difference by Mann-Whitney test, P=0.17) and by response duration (Fig. 5d ; no significant difference in hazard ratio, P=0.44). Thus, Page 18 a majority of ovarian PDX tumors respond strongly to a biomarker-guided treatment (ORR 88% in eligible tumors). Importantly, among the 38% of tumors that did not respond to paclitaxel/carboplatin, most (5 of 8) had a predictable objective response to one of these targeted therapies (Fig. 5e) , further supporting the hypothesis that biomarker-guided therapies may be an effective option for chemotherapyresistant ovarian cancers.
DISCUSSION
Approvals of the anti-angiogenesis inhibitor bevacizumab and PARP inhibitors have contributed to improved survival for ovarian cancer patients, however, the path to further progress has been unclear in the context of a difficult-to-target mutational landscape 26 . Moreover, standard combination chemotherapy is sufficiently effective to provide a high bar to a new therapy while nonetheless being ineffective for some patients and ultimately inadequate with respect to lasting control. The panel of patient-derived ovarian tumor xenografts described here was established to enable empirical comparison of multiple drug and drug combinations against chemotherapy at the level of individual human tumors.
The PDX models were established with the goal of capturing the clinically observed histological heterogeneity and mutational spectrum of human ovarian cancer. At present systemic chemotherapy for epithelial ovarian cancer is consistent across multiple histological subtypes, making it appropriate to study these subtypes together 4 . These PDXs as well as their genomic sequences are freely available to the research community through the PRoXe website (www.proxe.org) 27 .
Strong anti-tumor activity (greater than 25% ORR) was observed for three single agents and one synergistic drug combination, but as is common for targeted therapies, each drug or combination was active in only a subset of tumors. We identified genes whose expression was significantly associated with drug sensitivity for each of the four therapies (for olaparib, BRCA status is a established Page 19 biomarker 24 ), making it possible to stratify tumors into likely responders and non-responders. For example, a combination of the PI3K inhibitor BKM120 plus the MEK inhibitor binimetinib was most active in PDX tumors with low expression of the ABCG2 efflux pump, which has previously been shown to export binimetinib 20 ; we confimed that ABCG2 also predicts binimetinib response in breast cancer xenografts (Fig. 4b) . The performance of this biomarker, and others described in this study, was similar to that of BRCA loss-of-function mutations in predicting olaparib sensitivity, which is a clinical test in breast and ovarian cancers 24, 28 . In PDX models, four treatment options exhibited unstratified response rates between 31% and 48%, and choosing among these using biomarkers achieved an aggregate objective response rate of 88%. Thus nearly all PDX tumors tested had the potential to benefit from a biomarker-guided precision therapy approach.
Our data suggest that biomarkers other than oncogenic mutations or amplifications can be used to predict the effectiveness of a range of targeted therapies (e.g. antibody-drug conjugate, kinase inhibitor, inhibitor of a metabolic enzyme, etc); it is particularly helpful when these molecular features have a logical or mechanistic connection to drug response. In the case of ovarian cancer and the therapies studied here, analysis of biomarker prevalence in TCGA suggests that a precision medicine approach might be applicable to > 90% of patients. We note however, that the retrospective approach we used to identify predictive biomarkers does not involve verification in a second independent set of tumors (except in the case of ABCG2 and binimetinib 21 ). In addition, no pre-clinical study of a therapy is a guarantee of safety and efficacy in humans. Thus, the biomarkers described in this paper primarily constitute a proof of concept for precision therapy in ovarian cancer rather than an actionable set of predictions.
Possible clinical uses of biomarker-guided treatments for ovarian cancer include single-agent treatments Page 20
for relapsed or chemotherapy-resistant disease, maintenance therapies following an initial course of chemotherapy (as PARP inhibitors are currently used 29 ), or in combination with chemotherapy.
The present studies do not investigate responsiveness in the setting of recurrent disease, whose high incidence is a challenge in treating ovarian cancers. The likelihood of cross-resistance among targeted therapies and chemotherapy is also unclear, although at the population-level chemotherapy activity is correlated with olaparib activity, suggesting some cross-resistance, but not with other targeted therapies (HKT288, BKM120/binimetinib, LSU691), suggesting little cross-resistance in those cases. All of these questions can be subjected to pre-clinical investigation using additional PDX cohorts. Clinical testing of such a strategy, which is not limited to the therapies studied here, would most efficiently be conducted using a master protocol in which multiple biomarker-guided therapies are evaluated, as with the Lung-MAP trial 30 . 
